hydroxychloroquine + infliximab + methotrexate + prednisolone + sulfasalazine

This drug is a combination therapy consisting of five agents used primarily in the treatment of rheumatoid arthritis and other inflammatory autoimmune diseases. Each component has a distinct mechanism of action that contributes to controlling inflammation, modulating immune response, and preventing joint damage. - Hydroxychloroquine is an antimalarial drug with immunomodulatory effects; it interferes with antigen processing and presentation. - Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor alpha (TNF-α), blocking its pro-inflammatory activity. - Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase, leading to anti-inflammatory effects partly through adenosine pathway modulation. - Prednisolone is a synthetic glucocorticoid steroid that suppresses multiple inflammatory pathways by binding glucocorticoid receptors. - Sulfasalazine is another DMARD with anti-inflammatory properties whose exact mechanism involves inhibition of prostaglandin synthesis and modulation of immune cells. The combination leverages complementary mechanisms to improve symptom control and reduce disease progression more effectively than monotherapy or fewer drugs. It includes both conventional synthetic DMARDs, biologic therapy, and corticosteroid for rapid symptom relief.

Brand names

Plaquenil (hydroxychloroquine)Remicade (infliximab)Rheumatrex (methotrexate)no unique brand for prednisolone as it is genericAzulfidine (sulfasalazine)